DanStem is taking stem cell research to the next phase
Posted by Noami Dayan, on 24 August 2017
With a new grant of almost 15 million EUR from the Novo Nordisk Foundation, DanStem scientists will be focused on a new programme for translational hematology.
The Programme could have a major impact on treatment of haematological malignancies. The primary aim is to identify novel treatments for patients with blood cancers AML (Acute Myeloid Leukaemia) and MDS (Myelodysplastic Syndrome) for which treatments and success rates have changed little in the last decades.
Professor Kristian Helin will head the Programme, which will include collaboration with researchers from Rigshospitalet, Denmark’s largest hospital. Major activities include:
- Identifying and characterizing cancer stem cells from patients with blood cancer;
- Identifying the best available treatment for individual patients by screening patient-derived cancer stem cells for sensitivity toward a panel of approved drugs (personalized medicine); and
- Collaborating with companies to develop new drugs for treating blood cancer.
See more information here.
(No Ratings Yet)
Loading...